0001193125-23-060702.txt : 20230306 0001193125-23-060702.hdr.sgml : 20230306 20230306074600 ACCESSION NUMBER: 0001193125-23-060702 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230306 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230306 DATE AS OF CHANGE: 20230306 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Verrica Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001660334 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463137900 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38529 FILM NUMBER: 23707583 BUSINESS ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 BUSINESS PHONE: 484-453-3300 MAIL ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 8-K 1 d474665d8k.htm 8-K 8-K
false 0001660334 0001660334 2023-03-06 2023-03-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 6, 2023

 

 

Verrica Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-38529   46-3137900

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

44 W. Gay St., Suite

400 West Chester, PA

   19380
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (484) 453-3300

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

  

Trading

symbol

  

Name of each exchange

on which registered

Common Stock   VRCA   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On March 6, 2023, Verrica Pharmaceuticals Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

    Exhibit Description
99.1    Press Release, dated March 6, 2023
104   

Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Verrica Pharmaceuticals Inc.
Date: March 6, 2023      

/s/ P. Terence Kohler Jr.

      P. Terence Kohler Jr.
      Chief Financial Officer
 EX-99.1 2 d474665dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results

New Drug Application for VP-102 assigned PDUFA goal date of July 23, 2023

VP-102 has potential to address the approximately six million patients in the U.S. with molluscum contagiosum

Dosing of first patient in Part 2 of Phase 2 study of VP-315 for treatment of basal cell carcinoma expected in 2Q 2023

Raised gross proceeds of $32.5 million in secondary offering; pro forma cash and cash

equivalents to fund planned operations into 1Q 2024

WEST CHESTER, PA – March 6, 2023 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2022.

“We continue to execute across all aspects of our business, highlighted by the FDA’s recent acceptance of the filing of the resubmission of our NDA for VP-102, which is being developed for the treatment of molluscum contagiosum,” said Ted White, Verrica’s President and Chief Executive Officer. “Our potentially first-in-class oncolytic peptide immunotherapy, VP-315, for the treatment of basal cell carcinoma also continues to advance, and we remain on track to dose patients in Part 2 of our ongoing Phase 2 trial in the second quarter.

“In parallel with our regulatory and clinical accomplishments, we continue to make progress in our pre-commercial activities as we prepare for a potential U.S. launch of what could potentially be the first FDA-approved therapy for molluscum – a condition afflicting millions of children each year in the U.S. Utilizing our innovative “Buy-and-Bill” commercial model, we believe shelf-stable products for in-office administration such as VP-102 can be efficiently distributed to reach this large and underserved patient population with minimal capital outlay for dermatology practices.”

Business Highlights and Recent Developments

VP-102

 

  •  

On February 27, 2023, the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) of July 23, 2023 for Verrica’s New Drug Application (NDA) for VP-102, which is being developed for the treatment of molluscum contagiosum (molluscum). In January, the Company announced that it resubmitted the NDA for VP-102 for the treatment of molluscum to the FDA.

  •  

Verrica is seeking conditional approval to market VP-102 in the United States under the brand name YCANTH™. VP-102 is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. If approved, VP-102 would be the first product approved by the FDA to treat molluscum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children.

VP-315

 

  •  

Verrica expects to initiate Part 2 of its ongoing Phase 2 study in basal cell carcinoma in the second quarter of 2023. Part 2 is designed to confirm the exploratory dose from Part 1 and identify the recommended dosing regimen for Part 3 of the study. Cohorts will be expanded, and dosing evaluated based upon safety and efficacy results. VP-315 is a potentially first-in-class oncolytic peptide immunotherapy in development as a non-surgical treatment option for non-melanoma skin cancers. The Phase 2 trial is a three-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. The study is expected to enroll approximately 66 adult subjects with a histological diagnosis of basal cell carcinoma in at least one eligible target lesion.

Financial Results

Fourth Quarter 2022 Financial Results

 

  •  

Verrica recognized collaboration revenues of $0.1 million for the three months ended December 31, 2022, which was related to the Collaboration and License Agreement (Torii Agreement) with Torii Pharmaceutical Col, Ltd (Torii). Verrica did not recognize any revenue for the same period in 2021.

 

  •  

Verrica reported a net loss of $5.9 million for the fourth quarter of 2022, compared to a $9.5 million loss for the same period in 2021.

 

  •  

Research and development expenses were $3.0 million in the fourth quarter of 2022, compared to $3.4 million for the same period in 2021. The decrease was primarily attributable to a decrease in CMC costs related to Verrica’s development of VP-102 for molluscum contagiosum, external genital warts and common warts in 2022.

 

  •  

General and administrative expenses were $3.2 million in the fourth quarter of 2022, compared to $5.1 million for the same period in 2021. The decrease was primarily due to decreased headcount, a decrease in insurance, and other operating costs.

Full Year 2022 Financial Results

 

  •  

Verrica recognized collaboration revenues related to the Torii Agreement of $9.0 million for the year ended December 31, 2022 compared to $12.0 million for 2021. The current period collaboration revenue was related to an $8.0 million milestone payment and $1.0 million related to Torii’s purchase of supplies and reimbursement for development activities while the 2021 collaboration revenue was driven by the Torii upfront license milestone payment of $12.0 million.

 

  •  

Research and development expenses were $12.2 million for the year ended December 31, 2022, compared to $15.9 million for 2021. The decrease was primarily attributable decreased CMC and clinical costs related to Verrica’s development of VP-102 for molluscum contagiosum, external genital warts, and common warts in 2022, as well as a decrease of 1.3 million related to payments made to Lytix Biopharma AS (Lytix) upon the achievement of regulatory milestones for VP-315, during 2022 compared to 2021.

 

  •  

General and administrative expenses were $17.4 million for the year ended December 31, 2022, compared to $27.0 million for the same period in 2021. The decrease of $9.6 million was primarily a result of a decrease in expenses related to pre-commercial activities for VP-102 and decreases in headcount, insurance, professional fees, and other operating costs.

 

  •  

Costs of collaboration revenue were $0.7 million for the year ended December 31, 2022, compared to no costs for the year ended December 31, 2021. The costs of collaboration revenue during 2022 consisted of payments for manufacturing supply to support development and testing services pursuant to the clinical supply agreement with Torii.

 

  •  

For the year ended December 31, 2022, net loss on a GAAP basis was $24.5 million, or $0.72 per share, compared to a net loss of $35.1 million, or $1.30 per share, for the same period in 2021.

 

  •  

For the year ended December 31, 2022, non-GAAP net loss was $17.4 million, or $0.51 per share, compared to a non-GAAP net loss of $27.6 million, or $1.02 per share, for the same period in 2021.

 

  •  

As of December 31, 2022, Verrica had aggregate cash and cash equivalents of $34.3 million. In February 2023, the Company raised gross proceeds of approximately $32.5 million in an underwritten offering of its common stock and pre-funded warrants. Including the net proceeds received from this offering and the Company’s existing cash and cash equivalents as of December 31, 2022, Verrica believes it has sufficient cash and cash equivalents to support planned operations into the first quarter of 2024.

Non-GAAP Financial Measures

In evaluating the operating performance of its business, Verrica’s management considers non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share. These non-GAAP financial measures exclude stock-based compensation charges, loss on debt extinguishment and non-cash interest expense that are required by GAAP. Verrica believes that non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share provides useful information to both management and investors by excluding the effect of certain non-cash expenses and items that Verrica believes may not be indicative of its operating performance, because either they are unusual and Verrica does not expect them to recur in the ordinary course of its business, or they are unrelated to the ongoing operation of the business in the ordinary course. Non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share have been reconciled to the nearest GAAP measure in the tables following the financial statements in this press release.

About VP-102

Verrica’s lead product candidate, VP-102, is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. VP-102 could potentially be the first product approved by the FDA to treat molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Verrica is seeking conditional approval to market VP-102 in the United States under the brand name YCANTH™. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and a Phase 2 study of VP-102 for the treatment of external genital warts.

About Molluscum Contagiosum (Molluscum)

There are currently no FDA-approved treatments for molluscum, a highly contagious viral skin disease that affects approximately six million people — primarily children — in the United States. Molluscum is caused by a pox virus that produces distinctive raised, skin-toned-to-pink-colored lesions that can cause pain, inflammation, itching and bacterial infection. It is easily transmitted through direct skin-to-skin contact or through fomites (objects that carry the disease like toys, towels or wet surfaces) and can spread to other parts of the body or to other people, including siblings. The lesions can be found on most areas of the body and may carry substantial social stigma. Without treatment, molluscum can last for an average of 13 months, and in some cases, up to several years.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP- 315 (formerly LTX-315 and VP-LTX-315) for dermatologic oncology conditions. For more information, visit www.verrica.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current

beliefs and expectations. These forward-looking statements include expectations regarding the approval of VP-102 for the treatment of molluscum, the timing of clinical trial completion for VP-315 and Verrica’s cash and cash equivalents being sufficient to support planned operations into the first quarter of 2024. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica’s reliance on third parties over which it may not always have full control, uncertainties related to the COVID-19 pandemic and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2022 and other filings Verrica makes with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

VERRICA PHARMACEUTICALS INC.

Statements of Operations

(in thousands except share and per share data)

 

     Three Months Ended December 31,     Year Ended December 31,  
     2022     2021     2022     2021  

Collaboration revenue

    $ 68     $ —       $ 9,032     $ 12,000  

Expenses:

         

Research and development

      3,030       3,357       12,198       15,929  

General and administrative

      3,189       5,113       17,405       26,979  

Cost of collaboration revenue

      62       —         725       —    
  

 

 

    

 

 

    

 

 

    

 

 

  

Total expenses

      6,281       8,470       30,328       42,908  
  

 

 

    

 

 

    

 

 

    

 

 

  

Loss from operations

      (6,213 )      (8,470 )      (21,296 )      (30,908 ) 

Interest income

      287       27       476       123  

Interest expense

      —         (1,097 )      (2,172 )      (4,295 ) 

Loss on extinguishment of debt

      —         —         (1,437 )      —    

Other expense

      (6 )      —         (58 )      —    
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss

    $ (5,932 )    $ (9,540 )    $ (24,487 )    $ (35,080 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss per share, basic and diluted

    $ (0.14 )    $ (0.35 )    $ (0.72 )    $ (1.30 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Weighted average common shares outstanding, basic and diluted

      41,094,053       27,519,053       34,163,437       27,044,462  
  

 

 

    

 

 

    

 

 

    

 

 

  

VERRICA PHARMACEUTICALS INC.

Selected Balance Sheet Data

(in thousands)

 

     As of December 31,  
     2022      2021  

Cash, cash equivalents and marketable securities

    $ 34,273      $ 70,354  

Prepaid assets and other assets

      4,842        3,974  
  

 

 

     

 

 

  

Total current assets

      39,115        74,328  

PP&E, lease right of use asset, other

      5,606        5,797  
  

 

 

     

 

 

  

Total assets

    $  44,721      $  80,125  
  

 

 

     

 

 

  

Total liabilities

    $ 4,688      $ 47,520  

Total stockholders’ equity

      40,033        32,605  
  

 

 

     

 

 

  

Total

    $ 44,721      $ 80,125  
  

 

 

     

 

 

  

VERRICA PHARMACEUTICAS INC.

Reconciliation of Non-GAAP Financial Measures (unaudited)

(in thousands except per share data)

 

     Year Ended December 31, 2022  
     Loss from
Operations		     Net loss     Net loss per
share		  

GAAP

    $  (21,296 )    $  (24,487 )    $  (0.72 ) 

Non-GAAP Adjustments:

       

Stock-based compensation – Selling, General & Admin (a)

      3,525       3,525    

Stock-based compensation – Research & Development (a)

      1,460       1,460    

Loss on debt extinguishment

        1,437    

Non-cash interest expense (b)

        617    
  

 

 

    

 

 

    

 

 

  

Adjusted

    $  (16,311 )    $  (17,448 )    $  (0.51 ) 
  

 

 

    

 

 

    

 

 

  

     Year Ended December 31, 2021  
     Loss from
Operations		     Net loss     Net loss per
share		  

GAAP

    $  (30,908 )    $  (35,080 )    $  (1.30 ) 

Non-GAAP Adjustments:

       

Stock-based compensation – Selling, General & Admin (a)

      4,540       4,540    

Stock-based compensation – Research & Development (a)

      1,513       1,513    

Non-cash interest expense (b)

        1,412    
  

 

 

    

 

 

    

 

 

  

Adjusted

    $  (24,855 )    $  (27,615 )    $  (1.02 ) 
  

 

 

    

 

 

    

 

 

  

 

(a)

The effects of non-cash stock-based compensation are excluded because of varying available valuation methodologies and subjective assumptions. Verrica believes this is a useful measure for investors because such exclusion facilitates comparison to peer companies who also provide similar non-GAAP disclosures and is reflective of how management internally manages the business.

(b)

The effects of non-cash interest charges are excluded. Verrica believes such exclusion facilitates an understanding of the effects of the debt service obligations on the Company’s liquidity and comparisons to peer group companies and is reflective of how management internally manages the business.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

Terry Kohler

Chief Financial Officer

tkohler@verrica.com

Kevin Gardner

LifeSci Advisors

kgardner@lifesciadvisors.com

Chris Calabrese

LifeSci Advisors

ccalabrese@lifesciadvisors.com

EX-101.SCH 3 vrca-20230306.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 vrca-20230306_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 vrca-20230306_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g474665g0304015030276.jpg GRAPHIC begin 644 g474665g0304015030276.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Mar. 06, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001660334
Document Type 8-K
Document Period End Date Mar. 06, 2023
Entity Registrant Name Verrica Pharmaceuticals Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38529
Entity Tax Identification Number 46-3137900
Entity Address, Address Line One 44 W. Gay St.
Entity Address, Address Line Two Suite
Entity Address, City or Town 400 West Chester
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19380
City Area Code (484)
Local Phone Number 453-3300
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol VRCA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
XML 8 d474665d8k_htm.xml IDEA: XBRL DOCUMENT 0001660334 2023-03-06 2023-03-06 false 0001660334 8-K 2023-03-06 Verrica Pharmaceuticals Inc. DE 001-38529 46-3137900 44 W. Gay St. Suite 400 West Chester PA 19380 (484) 453-3300 false false false false Common Stock VRCA NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d474665d8k.htm d474665dex991.htm vrca-20230306.xsd vrca-20230306_lab.xml vrca-20230306_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d474665d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d474665d8k.htm" ] }, "labelLink": { "local": [ "vrca-20230306_lab.xml" ] }, "presentationLink": { "local": [ "vrca-20230306_pre.xml" ] }, "schema": { "local": [ "vrca-20230306.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vrca", "nsuri": "http://www.verrica.com/20230306", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d474665d8k.htm", "contextRef": "duration_2023-03-06_to_2023-03-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d474665d8k.htm", "contextRef": "duration_2023-03-06_to_2023-03-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-23-060702-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-060702-xbrl.zip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end